BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33763292)

  • 1. Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse.
    Kamal Y; Dwan D; Hoehn HJ; Sanz-Pamplona R; Alonso MH; Moreno V; Cheng C; Schell MJ; Kim Y; Felder SI; Rennert HS; Melas M; Lazaris C; Bonner JD; Siegel EM; Shibata D; Rennert G; Gruber SB; Frost HR; Amos CI; Schmit SL
    Oncoimmunology; 2021 Mar; 10(1):1862529. PubMed ID: 33763292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
    Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
    Alwers E; Kather JN; Kloor M; Brobeil A; Tagscherer KE; Roth W; Echle A; Amitay EL; Chang-Claude J; Brenner H; Hoffmeister M
    J Pathol Clin Res; 2023 Mar; 9(2):129-136. PubMed ID: 36424650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
    Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
    Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
    Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
    Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients.
    Ke J; Liu XH; Jiang XF; He Z; Xiao J; Zheng B; Chen YF; Cai ZR; Zheng XB; Zou YF; Lan P; Wu XJ; Gao F
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e62-e70. PubMed ID: 32863096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.
    Chen YJ; Luo SN; Dong L; Liu TT; Shen XZ; Zhang NP; Liang L
    J Transl Med; 2021 Sep; 19(1):379. PubMed ID: 34488791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtype identification and prognosis stratification by a metabolism-related gene expression signature in colorectal cancer.
    Lin D; Fan W; Zhang R; Zhao E; Li P; Zhou W; Peng J; Li L
    J Transl Med; 2021 Jun; 19(1):279. PubMed ID: 34193202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.
    Pentheroudakis G; Raptou G; Kotoula V; Wirtz RM; Vrettou E; Karavasilis V; Gourgioti G; Gakou C; Syrigos KN; Bournakis E; Rallis G; Varthalitis I; Galani E; Lazaridis G; Papaxoinis G; Pectasides D; Aravantinos G; Makatsoris T; Kalogeras KT; Fountzilas G
    PLoS One; 2015; 10(5):e0124612. PubMed ID: 25970543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.
    O'Cathail SM; Wu CH; Lewis A; Holmes C; Hawkins MA; Maughan T
    Cancer Genet; 2020 Oct; 248-249():1-10. PubMed ID: 32871287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Autophagy in Tumor Immune Infiltration in Colorectal Cancer.
    Bian-Fang Y; Dong-Ning W; Dan T; Jian-Yu S; Shi-Yi W; Ben-Jun W; Xin D; Wen-Wen Z; Qing-Feng W; Yan Z
    Anal Cell Pathol (Amst); 2022; 2022():2055676. PubMed ID: 35321516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated Profiling Identifies
    Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
    Front Immunol; 2021; 12():722807. PubMed ID: 34646265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
    Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
    Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
    Khaliq AM; Erdogan C; Kurt Z; Turgut SS; Grunvald MW; Rand T; Khare S; Borgia JA; Hayden DM; Pappas SG; Govekar HR; Kam AE; Reiser J; Turaga K; Radovich M; Zang Y; Qiu Y; Liu Y; Fishel ML; Turk A; Gupta V; Al-Sabti R; Subramanian J; Kuzel TM; Sadanandam A; Waldron L; Hussain A; Saleem M; El-Rayes B; Salahudeen AA; Masood A
    Genome Biol; 2022 May; 23(1):113. PubMed ID: 35538548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B.
    Daemen A; Udyavar AR; Sandmann T; Li C; Bosch LJW; O'Gorman W; Li Y; Au-Yeung A; Takahashi C; Kabbarah O; Bourgon R; Hegde P; Bais C; Das Thakur M
    PLoS One; 2021; 16(12):e0262198. PubMed ID: 34972191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer.
    Ge P; Wang W; Li L; Zhang G; Gao Z; Tang Z; Dang X; Wu Y
    Biomed Pharmacother; 2019 Oct; 118():109228. PubMed ID: 31351430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.